17.64
+0.17%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wuhan Hvsen Biotechnology Co
Its shares trade on Shenzhen under the ticker 300871.SZ. It has been listed since 24 August 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.68bn and net income of CN¥253.2m. At that date it held total assets of CN¥3.01bn and shareholders' equity of CN¥2.17bn.
HVSEN Biotechnology Co., Ltd. engages in the research and development, production, and sale of veterinary drugs. The company is headquartered in Wuhan, Hubei. The company went IPO on 2020-08-24. The Company’s main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The firm mainly conducts its businesses in the China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Aug 2020
- Employees
- 957
- Website
- whhsyy.com ↗
Leadership
Pay as last reported
- Mr. Weiyuan ZhangChairman of the BoardCN¥1.1m
- Mr. Kaijie YangChief Financial Officer, Deputy General ManagerCN¥666,300
- Ms. Jian ZhouChief Human Resources OfficerCN¥259,600
- Mr. Jie HanRotating General Manager
- Mr. Jinbin HuangDeputy General ManagerCN¥754,900
- Mr. Shuo LiDeputy General Manager
- Mr. Yanshu WuDeputy General Manager
- Mr. Hujie YuDeputy General Manager
- Mr. Qingfeng WangSecretary of the Board
- Mr. Hongbo ChenDirector
- Mr. Zexiang LiuDirector
- Mr. Xianxue YaoDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wuhan Hvsen Biotechnology employs 957 full-time employees in Wuhan, China.
- HVSEN Biotechnology focuses on veterinary pharmaceuticals and traditional Chinese medicine preparations.
- The company's main products include tyvanicin tartrate and florfenicol powder for veterinary use.
Weaknesses
- The company operates solely in the China market without international expansion.
- HVSEN Biotechnology has no presence in the global veterinary drug market.
- The firm's business is limited to veterinary pharmaceuticals without diversification.
Opportunities
- The Chinese veterinary drug market shows growth potential for HVSEN Biotechnology.
- Expanding into feed additives could leverage existing product lines.
- Increasing demand for veterinary traditional Chinese medicine preparations offers opportunities.
Threats
- Competition from domestic veterinary pharmaceutical companies in China.
- Regulatory changes in China's veterinary drug industry could impact operations.
- Economic downturns in China may affect the veterinary drug market demand.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.